Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Neurol ; 72(5): 816-20, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23280797

RESUMEN

Coordinated reset neuromodulation consists of the application of consecutive brief high-frequency pulse trains through the different contacts of the stimulation electrode. In theoretical studies, by achieving unlearning of abnormal connectivity between neurons, coordinated reset neuromodulation reduces pathological synchronization, a hallmark feature of Parkinson's disease pathophysiology. Here we show that coordinated reset neuromodulation of the subthalamic nucleus has both acute and sustained long-lasting aftereffects on motor function in parkinsonian nonhuman primates. Long-lasting aftereffects were not observed with classical deep brain stimulation. These observations encourage further development of coordinated reset neuromodulation for treating motor symptoms in Parkinson disease patients.


Asunto(s)
Intoxicación por MPTP/complicaciones , Desempeño Psicomotor/fisiología , Animales , Estudios Cruzados , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Terapia por Estimulación Eléctrica/métodos , Macaca mulatta , Núcleo Subtalámico/fisiología , Resultado del Tratamiento
2.
Nat Rev Drug Discov ; 10(5): 377-93, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21532567

RESUMEN

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting tremors. Although these symptoms can be improved using currently available dopamine replacement strategies, there is still a need to improve current strategies of treating these symptoms, together with a need to alleviate non-motor symptoms of the disease. Moreover, treatments that provide neuroprotection and/or disease-modifying effects remain an urgent unmet clinical need. This Review describes the most promising biological targets and therapeutic agents that are currently being assessed to address these treatment goals. Progress will rely on understanding genetic mutations or susceptibility factors that lead to Parkinson's disease, better translation between preclinical animal models and clinical research, and improving the design of future clinical trials.


Asunto(s)
Antiparkinsonianos/farmacología , Sistemas de Liberación de Medicamentos , Enfermedad de Parkinson/tratamiento farmacológico , Animales , Ensayos Clínicos como Asunto/métodos , Modelos Animales de Enfermedad , Dopamina/metabolismo , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Neuronas/patología , Enfermedad de Parkinson/fisiopatología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA